Our Approach

Targeting long non-coding RNAs for the safer and more effective tissue-specific treatment of fibrotic diseases and other serious medical conditions

The Science

Long Non-Coding RNAs (lncRNAs)

The Science

Long Non-Coding RNAs (IncRNAs)
Pie chart representing total human genome: >80% genome correspond to non-coding RNAs; <2% to protein coding RNAs

The non-coding portion of the genome, known as ‘dark matter’, is dynamically active, generating thousands of therapeutically unexplored long non-coding RNAs

LncRNAs interact with proteins and nuclei acids, DNA and RNA, at nucleus and cytoplasmic compartment of the cell

IncRNAs are a unique class of regulatory molecules that bridge the analog world of proteins with the digital world of nucleic acids both DNA & RNA to regulate disease associated cellular processes in response to the environment

Environmental stimuli activate lncRNAs and lncRNAs consequently regulate epigenomic networks

IncRNAs process and integrate environmental signals to modulate the epigenome, regulating key drivers of chronic disease processes associated with fibrosis and aging

The Science

Long Non-Coding RNAs (lncRNAs)

Our Solution

Inhibiting pro-fibrotic lncRNAs
Human body with zoom-in into the heart tissue. heart tissue zoom-in into the fibroblast cell
In the right place

HAYA has developed proprietary tools and methods to interrogate lncRNA biology, identifying exquisitely tissue- and cell-type specific therapeutic targets

Stress environmental stimuli activates lncRNA. lncRNA trigger fibrosis pathways, converting fibroblasts into myofibroblast
At the right time

Specific lncRNAs are important regulators of the resting fibroblast to myofibroblast conversion, resulting in fibrosis and disease

ASO Image
In the right way

HAYA is utilizing emerging RNA-targeting modalities, such as modified antisense oligonucleotides (ASOs), to target and inhibit proprietary lncRNAs to prevent and reverse fibrosis

triangle describing HAYA guiding principles, safe with a cross, effective with an arrow and accessible with a timer

Haya's mission

The rapid development of anti-fibrotic therapeutics that are safe, effective and accessible.

The Science

Long Non-Coding RNAs (lncRNAs)

Our Discovery Program

Line of organs with heart highlighted. Below an inverted cone shape graph with filtering analysis steps ending up with 3 targets lncRNAs

Our proprietary drug discovery engine enables us to discover and generate a pipeline of lncRNA targeting anti-fibrotic candidates for many tissues including lung, kidney, liver and the tumor microenvironment. These lead targets have the potential for significantly greater efficacy, safety and accessibility than existing treatments


HAYA's initial focus is the development of precision genomic medicines for fibrotic diseases and other serious health conditions associated with aging.

HAYA is utilizing DiscoverHAYA™️ to identify lead candidates for other fibrotic indications in tissues including the lung, kidney, liver, skin and tumor microenvironment.

Click here to learn more about HAYA leading therapeutics candidates.

Through our proprietary DiscoverHAYA engine and pipeline, HAYA is developing potent and selective next-generation therapeutics based on our unique ability to address the RIGHT TARGET, TISSUE, TIME & WAY
Illustrations by Ana Silva. Website by Autobahn Design.
Made with